TD-08 High type I interferon activity is associated with active class III/IV lupus nephritis in european-american lupus patients independent of anti-dsDNA antibodies. (August 2018)

• Record Type: Journal Article
• Authors: Iwamoto, Taro; Dorschner, Jessica M; Jensen, Mark A; Vsetecka, Danielle; Amin, Shreyasee; Makol, Ashima; Ernste, Floranne C; Osborn, Thomas; Moder, Kevin; Chowdhary, Vaidehi; Niewold, Timothy B
• Is Part Of: Lupus science & medicine. Volume 5(2018)Supplement 2
• Page Start: A75
• Page End: A76
• Publication Date: 2018-08
• Subjects: Systemic lupus erythematosus -- Periodicals; 616.772005
• DOI: 10.1136/lupus-2018-lsm.127
• Languages: English
• ISSNs: 2398-8851

Abstract

Abstract : Background: Lupus nephritis (LN) is one of the most severe types of organ involvement in systemic lupus erythematosus (SLE), despite the recent advances in immunosuppressive therapies. High type I interferon (IFN) is a heritable risk for SLE, and some previous studies have suggested a link between high IFN and lupus nephritis. However, little is known about the relationships between high levels of IFN and the subtypes of LN, and whether IFN is more associated with anti-dsDNA antibodies or with clinical nephritis. Methods: We studied 244 European-American (EA) SLE patients and measured type I IFN in sera by performing WISH IFN bioassay as described previously. Subtypes of LN were confirmed by renal biopsy review. Complements, anti-dsDNA and other auto-antibodies were measured in the clinical laboratory, and standard clinical cut-offs were used to define a positive result. Non-parametric analyses were used to compare IFN data with the clinical data. RNA in-situ hybridization was used to assess markers of plasmacytoid dendritic cells (PDCs) and IFN-induced gene expression in renal biopsy samples. Results: IFN level and SLEDAI score was positively correlated (r=0.26, p<0.0001, Spearman) in our cross-sectional evaluation. EA subjects with a high level of IFN (IFN score ≥2) were more likely to have renal manifestations compared to the subjects with a low level of IFN (IFN score <2) (p<0.001, OR=3.0, Fisher's exact test). In addition, the incidence rate of class III/IV LN was significantly higher among patients with a high level of IFN compared to the patients with low levels of IFN (p<0.01, OR=5.5, Fisher's exact test). Notably, IFN level was significantly higher in active class III/IV LN compared to inactive class III/IV LN (p<0.05 Mann-Whitney U) and this was not observed in non-class III/IV LN populations. Positivity of ds-DNA antibody did not show significant difference between inactive class III/IV LN and active class III/IV LN. Using RNA- in-situ hybridization methods, we document infiltration of class III/IV nephrtis biopsy tissue with PDCs with IFN-signature positive cells surrounding them, supporting local production of type I IFNs. Conclusions: Our data support an association between type I IFN and class III/IV nephritis that is independent of overall SLEDAI and anti-dsDNA antibodies, suggesting that IFN is involved in renal pathogenesis. These data also suggest that IFN could predict renal disease activity or the future risk of developing LN, especially class III/IV LN in EA SLE patients.